Xcovery LLC
www.xcovery.com
Latest From Xcovery LLC
Betta Pins Hopes On New Overseas JV Amid Challenges
Betta Pharmaceuticals hopes strategic initiatives overseas will facilitate its diversification away from a single dominant oncology product. The Chinese firm is facing increasing competition from domestic generics, with revenues and profits under pressure.
ALEX Ups The Ante For Alecensa In ALK+ NSCLC
Roche's Alecensa has bested Pfizer's Xalkori in the Phase III head-to-head ALEX study in first-line non-small-cell lung cancer, making a strong case for it to be the new gold standard therapy in ALK-positive patients, in favor of Novartis's Zykadia.
China VC Roundup: Investors Flock To Rising Innovation, Expertise
The past few months have seen frenzied venture capital and other investment in the Chinese pharma and biotech space, driven by increasingly innovative startups run by big pharma veterans, while corporate ventures have been joining with private equity to build up specialist investment and M&A funds.
Betta IPO: New Hope For Made In China Innovation?
The successful IPO of China's drug innovation darling Betta may herald a new wave of capital inflow and renewed interest in new drug R&D in China, but hurdles to the pursuit of original research remain.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- Xcovery Inc.
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Xcovery LLC
- Senior Management
-
Michael D Webb, Pres. & CEO
Chris Liang, PhD, EVP & CSO
Cheryl Calhoun, VP, Bus. Dev. - Contact Info
-
Xcovery LLC
Phone: (561) 835-9356
505 S. Flagler Dr.
Ste. 1330
West Palm Beach, FL 33401
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice